Different driver mutations have been identified in NSCLC, including oncogenic mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, ROS1, and MET (52). Here, EGFR is linked to non-small cell lung carcinoma.